Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06699901 · ClinicalTrials.gov registry record
Antibiotic Concentrations After MassivE Transfusion Study
A clinical trial of Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents, sponsored by Brooke Army Medical Center.
- Recruiting
- Registry status
- 417
- Enrollment target
- 2
- Study locations
NCT06699901: Recruiting study of Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents, sponsored by Brooke Army Medical Center.
NCT06699901 is a study of Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents that is actively recruiting participants, run by Brooke Army Medical Center. The registered enrollment target is 417 participants. The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06699901, a study of Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents, is actively recruiting participants, sponsored by Brooke Army Medical Center.
- RECRUITING
- Registry status
- 417 participants
- Enrollment target
- 2
- Study locations
Study Summary
Combat and civilian trauma frequently result in open wounds that are at risk for infection. Data from the Department of Defense Trauma Registry demonstrate that 74% of combat trauma casualties have an open wound. The Committee on Tactical Combat Casualty Care, the Prolonged Field Care Working Group, and the Joint Trauma System clinical practice guidelines recommend antibiotic prophylaxis for open wounds after trauma. The civilian setting has similar risks of open wound infection after trauma. In parallel, current practice guidelines recommend the aggressive use of balanced blood products during resuscitation. It remains unclear how the replacement of blood after hemorrhage through transfusion may affect antibiotic concentrations. Data is necessary to better understand this relationship to enhance wound prophylaxis antibiotic dosing, particularly in severely wounded casualties who receive blood products during massive transfusions. It remains unclear how these resuscitation methods may alter pharmacokinetics. The investigators hypothesize that drug concentrations decrease in direct relation to the amount of blood transfused during low-volume, massive, and supermassive transfusion after trauma compared to patients who receive no blood products. The investigators seek to understand the relationship between drug concentrations and blood product administration using a non-compartmentalized model in the setting of hemorrhage. Specifically, they will (1) obtain drug concentrations at regular intervals during the first 12-18 hours after administration of antibiotics, (2) determine how much blood products and fluids are transfused during the 12 hours prior to antibiotic and 24 hours post-administration, and (3) perform data modeling to understand the relationship between blood transfusions and drug concentrations to inform data-driven dosing models. Liquid chromatography methods will be developed to measure drug concentrations. The investigators will conduct a prospective, m
Primary Outcome
Obtain drug concentrations at regular intervals during the first 18 hours after antibiotic administration.
Conditions Studied
Interventions
- OTHER Control Group
- OTHER Massive Transfusion Group
Study Locations (2)
Colorado
- University of Colorado Hospital - Aurora
Texas
- Brooke Army Medical Center - Fort Sam Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2024-09-30 |
| Est. Completion | 2027-09-30 |
What NCT06699901 shows while recruiting
NCT06699901 is an observational study that tracks outcomes without assigning an intervention. The registered 417 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents appearing as the primary indexed condition, and to 2 interventions - of which Control Group is the first listed.
NCT06699901 reports a single indexed study location in Colorado, Texas.
Frequently Asked Questions
What is clinical trial NCT06699901 about?
NCT06699901 is a clinical study titled "Antibiotic Concentrations After MassivE Transfusion Study". Combat and civilian trauma frequently result in open wounds that are at risk for infection. Data from the Department of Defense Trauma Registry demonstrate that 74% of combat trauma casualties have an open wound. The Committee on Tactical Combat Casualty Care, the Prolonged Field Care Working Group,...
What is the current status of trial NCT06699901?
This trial is currently recruiting. The enrollment target is 417 participants. The study started on 2024-09-30. Estimated completion is 2027-09-30.
What conditions does trial NCT06699901 study?
This clinical trial studies the following conditions: Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Affecting Blood Constituents.
What interventions are being tested in trial NCT06699901?
The interventions under investigation include: Control Group (OTHER), Massive Transfusion Group (OTHER).
Who is sponsoring clinical trial NCT06699901?
This trial is sponsored by Brooke Army Medical Center, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06699901 being conducted?
This trial has 2 study locations across Colorado, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06169735 · 417 participants · Phase 4
Does Fluorescence With or Without Indocyanine Green Improve Parathyroid Identification and Preservation
- NCT03135886 · 418 participants · NA
Project I Test: Implementing HIV Testing in Opioid Treatment Programs
- NCT03527537 · 416 participants · Phase 4
Gestational Diabetes and Pharmacotherapy (GAP)
- NCT05007782 · 416 participants · Phase 1
Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI